ArticleNeurogenesis (Austin, Tex.)2017
Epigallocatechin gallate: A useful therapy for cognitive disability in Down syndrome?
Article in Neurogenesis (Austin, Tex.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 17 citations in OpenAlex.
- Clinical insights into catechin-based nanomedicine: a review of therapeutic potential in neurodegenerative diseases.3 Biotech · 2025Review
- MultimodalFrontiers in medicine · 2022Article
- Impaired Brain Mitochondrial Bioenergetics in the Ts65Dn Mouse Model of Down Syndrome Is Restored by Neonatal Treatment with the Polyphenol 7,8-Dihydroxyflavone.Antioxidants (Basel, Switzerland) · 2021Article
- From the lab to the people: major challenges in the biological treatment of Down syndrome.AIMS neuroscience · 2021Review
- Accelerated bio-cognitive aging in Down syndrome: State of the art and possible deceleration strategies.Aging cell · 2019Review
- Downregulated Wnt/β-catenin signalling in the Down syndrome hippocampus.Scientific reports · 2019Article
- Outer Brain Oscillations in Down Syndrome.Frontiers in systems neuroscience · 2019Review
- Can EGCG Alleviate Symptoms of Down Syndrome by Altering Proteolytic Activity?International journal of molecular sciences · 2018Review
- Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits.Molecular genetics & genomic medicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodevelopmental alterations and cognitive disability are constant features of Down syndrome (DS), a genetic condition due to triplication of chromosome 21.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.